It was a privilege to contribute to the Jake Javier interview with CNN’s Dr. Sanjay Gupta which aired today. Jake continues to be an inspiration to all of us, almost ten years following his treatment with Lineage’s OPC1 cell transplant. Watch for more: https://lnkd.in/eiQbTBzf #SCI #SpinalCordInjury #ReplaceandRestore
Lineage Cell Therapeutics
生物技术研究
Carlsbad，CA 5,582 位关注者
A clinical-stage biotechnology company developing novel cell therapies for unmet medical needs.
关于我们
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical assets include (i) OpRegen?, a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com.
- 网站
-
https://www.lineagecell.com
Lineage Cell Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Carlsbad，CA
- 类型
- 上市公司
- 创立
- 1990
地点
Lineage Cell Therapeutics员工
动态
-
Lineage Cell Therapeutics reports fourth quarter and full year 2024 financial and operating results and will host a conference call today at 4:30 pm ET / 1:30 pm PT. Learn more: https://bit.ly/4idX7re #ReplaceAndRestore
-
-
Lineage Cell Therapeutics will report fourth quarter and full year 2024 financial results on Monday, March 10, 2025, and host a conference call at 4:30 pm ET / 1:30 pm PT to provide a business update. Learn more: https://bit.ly/41HOm2P #ReplaceAndRestore
-
-
Join Lineage Cell Therapeutics’ CEO Brian Culley for his presentation at Biocom California’s Global Life Science Partnering & Investor Conference in La Jolla, CA, on February 26, 2025. For more about the conference: https://bit.ly/3xLb8qT #ReplaceAndRestore #BiocomGPIC
-
-
Join Brian Culley, CEO of Lineage Cell Therapeutics, as he presents at the H.C. Wainwright & Co., LLC’s 3rd Annual Cell Therapy Virtual Conference on February 25, 2025. Qualified investors can register here: https://lnkd.in/dSQTZqkm #ReplaceAndRestore #RegenerativeMedicine
-
-
Did you miss CEO Brian Culley's Lineage Cell Therapeutics presentation at the Oppenheimer 35th Annual Healthcare Life Sciences Conference? A webcast recording is now available. For more: https://bit.ly/40PQAM5 Oppenheimer & Co. Inc., #OPCOLifeSciences #ReplaceandRestore
-
-
Join Lineage Cell Therapeutics' CEO Brian Culley today at 12:40 pm ET for his presentation and Q&A at the Oppenheimer 35th Annual Healthcare Life Sciences Conference. For more: https://lnkd.in/eKyNqvMv Oppenheimer & Co. Inc., #OPCOLifeSciences #ReplaceandRestore
-
-
Lineage Cell Therapeutics has initiated the DOSED clinical study of OPC1, its allogeneic cell transplant therapy for spinal cord injury. The study will enroll both subacute and chronic patients, marking an important step in advancing treatment options. UC San Diego Health is the first study site. Learn more: https://bit.ly/3CMUxsK California Institute for Regenerative Medicine (CIRM) | #ReplaceandRestore #ClinicalTrials
-
-
Watch Lineage Cell Therapeutics’ CEO Brian Culley present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11 at 12:40 PM ET. A replay will be available after the session. For more: https://lnkd.in/egCzZeEk Oppenheimer & Co. Inc., #OPCOLifeSciences #ReplaceandRestore
-
-
Join Lineage Cell Therapeutics’ CEO Brian Culley at the Hearing Therapeutics Summit 2025, hosted by Hearing Health & Technology Matters. This virtual event runs February 4–5, with Brian joining the live panel "Transforming Patient Care: Clinical Applications and the Road Ahead" on February 5. Panelists include: ? Celia Belline, Founder & CEO, Cilcare ? Jonathan Kil, MD, PhD, CEO & CMO, Sound Pharmaceuticals, Inc. ? Jason Leyendecker, AuD, Private Practice Owner, Board Member & Past-President, Academy of Doctors of Audiology ? Kevin Liebe, AuD, President & CEO, Hearing Health & Technology Matters ? Moderated by Brian Taylor, AuD, Senior Director of Audiology at Signia Hearing ?? Register now to be part of the conversation: https://lnkd.in/gwfxpp_m #HearingLoss #RegenerativeMedicine
-